How Natriuretic Peptides Protect Heart and Kidneys
Natriuretic Peptides
3 Peptides, One Defense System
ANP, BNP, and CNP form a coordinated hormonal system that protects the heart from hypertrophy and fibrosis while preserving kidney filtration under cardiac stress.
Goetze et al., Nature Reviews Cardiology, 2020
Goetze et al., Nature Reviews Cardiology, 2020
View as imageThe heart is an endocrine organ. That discovery, made in the 1980s, revealed that atrial cardiomyocytes produce and secrete peptide hormones that regulate blood pressure, fluid balance, and organ protection across the cardiovascular and renal systems. Goetze et al. (2020) reviewed six decades of research in Nature Reviews Cardiology, documenting how atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) exert pleiotropic effects through the guanylyl cyclase A receptor (GC-A) and the second messenger cGMP.[1] For an introduction to ANP, see ANP: the atrial peptide that lowers blood pressure. For the diagnostic side, see BNP and NT-proBNP: the heart failure blood tests explained.
Key Takeaways
- ANP, BNP, and CNP activate guanylyl cyclase receptors (GC-A and GC-B) to produce cGMP, which drives vasodilation, natriuresis, and anti-fibrotic effects through PKG signaling[1]
- Natriuretic peptides directly suppress the renin-angiotensin-aldosterone system (RAAS) at multiple levels: renin secretion, aldosterone synthesis, and sympathetic nerve activity[2]
- Mice lacking GC-A develop cardiac hypertrophy and fibrosis even without hemodynamic stress, confirming a direct anti-remodeling role (Kuwahara, 2021)[3]
- Inoue et al. (2025) showed deletion of natriuretic peptide/GC-A signaling accelerated diabetic kidney disease, while finerenone rescued the effect[4]
- A defective natriuretic peptide system is linked to obesity and predicts type 2 diabetes risk (Moro, 2016)[5]
- Panneflek et al. (2025) identified natriuretic peptides as regulators of cardiovascular, renal, metabolic, and immune pathways, not just volume biomarkers[6]
The Three Natriuretic Peptides
ANP (Atrial Natriuretic Peptide)
ANP is a 28-amino-acid peptide produced primarily by atrial cardiomyocytes. It is stored in secretory granules and released in response to atrial wall stretch, which occurs when blood volume or pressure rises. ANP was the first natriuretic peptide discovered, establishing the heart's endocrine function. Its primary actions include vasodilation, natriuresis (sodium excretion by the kidneys), and suppression of the RAAS. Goetze et al. (2020) described ANP as the peptide that initiated the field of modern research on the heart as an endocrine organ.[1]
BNP (B-Type Natriuretic Peptide)
BNP is a 32-amino-acid peptide produced mainly by ventricular cardiomyocytes. Unlike ANP, which is stored and released rapidly, BNP is primarily regulated at the transcriptional level: gene expression increases in response to ventricular wall stress, with secretion following within hours. BNP shares ANP's receptor (GC-A) and produces similar downstream effects, but its ventricular origin means it responds specifically to ventricular overload. This is why BNP and its precursor fragment NT-proBNP are the primary blood tests for heart failure diagnosis.[1]
CNP (C-Type Natriuretic Peptide)
CNP is a 22-amino-acid peptide produced primarily by endothelial cells rather than cardiomyocytes. It acts through a different receptor, guanylyl cyclase B (GC-B), and has distinct functions: vasodilation, anti-proliferative effects on vascular smooth muscle, and bone growth regulation. CNP has less natriuretic (sodium-excreting) activity than ANP or BNP but stronger anti-fibrotic and anti-hypertrophic effects on blood vessels. Sangaralingham et al. (2023) identified CNP's vascular and cardiac protective properties as a therapeutic target, noting that CNP-based therapies could complement ANP/BNP-based approaches.[7]
The cGMP-PKG Signaling Pathway
All cardioprotective and renoprotective effects of natriuretic peptides converge on a single intracellular signaling cascade: cGMP-PKG.
When ANP or BNP binds GC-A (or CNP binds GC-B), the receptor's intracellular domain catalyzes conversion of GTP to cyclic guanosine monophosphate (cGMP). cGMP activates protein kinase G (PKG), which phosphorylates downstream targets that produce the specific protective effects:
- Vasodilation: PKG phosphorylates myosin light chain phosphatase in vascular smooth muscle, causing relaxation and reduced peripheral resistance
- Natriuresis: in kidney tubular cells, cGMP inhibits sodium reabsorption channels (ENaC), promoting sodium and water excretion
- Anti-hypertrophy: PKG phosphorylates and inhibits calcineurin/NFAT signaling in cardiomyocytes, blocking the hypertrophic gene program
- Anti-fibrosis: cGMP/PKG inhibits TGF-beta signaling in cardiac fibroblasts, reducing collagen deposition
Panneflek et al. (2025) synthesized this evidence in a comprehensive review, describing natriuretic peptides as "multisystem regulators" that extend far beyond their role as volume biomarkers. Their cGMP-PKG signaling regulates cardiovascular, renal, metabolic, and immune pathways simultaneously.[6]
How Natriuretic Peptides Protect the Heart
Opposing the RAAS
The renin-angiotensin-aldosterone system (RAAS) drives sodium retention, vasoconstriction, and cardiac remodeling. Natriuretic peptides are the endogenous counterbalance. Silver (2006) described the natriuretic peptide system as primarily maintaining fluid and pressure homeostasis by modulating cardiac and renal function, with direct antagonism of RAAS at every level.[2]
Specific RAAS suppression mechanisms:
- Renin: ANP directly inhibits renin secretion from juxtaglomerular cells in the kidney
- Aldosterone: ANP and BNP suppress aldosterone synthesis in the adrenal zona glomerulosa
- Angiotensin II: natriuretic peptides functionally oppose angiotensin II's vasoconstrictive and pro-fibrotic effects through competing cGMP signaling
- Sympathetic tone: ANP reduces sympathetic nerve activity, lowering heart rate and catecholamine release
Diez (2017) proposed that chronic heart failure represents a state of "reduced effectiveness" of the natriuretic peptide system, where despite elevated ANP and BNP levels, the compensatory effects become insufficient against sustained RAAS activation.[8]
Preventing Cardiac Hypertrophy and Fibrosis
Beyond hemodynamic effects, natriuretic peptides directly protect the heart muscle from structural damage. Kuwahara (2021) reviewed evidence showing that mice genetically lacking GC-A (the ANP/BNP receptor) develop cardiac hypertrophy and fibrosis spontaneously, even in the absence of high blood pressure or volume overload.[3] This means natriuretic peptides are not just responding to cardiac stress; they are actively preventing it under normal conditions.
The anti-hypertrophic mechanism operates through PKG-mediated inhibition of the calcineurin/NFAT pathway, a central driver of pathological cardiac growth. The anti-fibrotic effect involves suppression of TGF-beta signaling in cardiac fibroblasts, reducing the collagen deposition that stiffens the heart and impairs filling. Giovou et al. (2024) showed that both NPPA (ANP gene) and NPPB (BNP gene) are induced by cardiac stress and serve not only as markers but as active protective agents during cardiovascular dysfunction.[9]
Protection During Ischemia
Tourki et al. (2019) demonstrated acute cardioprotection with Lebetin 2, a snake venom-derived B-type natriuretic peptide. A single injection before or after myocardial ischemia-reperfusion reduced infarct size and improved left ventricular function in mice. The protective effect persisted for weeks, with reduced post-infarction inflammation and fibrosis. This suggests that natriuretic peptide signaling has acute protective effects during ischemic events beyond its chronic homeostatic functions.[10]
How Natriuretic Peptides Protect the Kidneys
Renal Hemodynamics
Natriuretic peptides increase glomerular filtration rate (GFR) through a specific hemodynamic mechanism: they dilate the afferent arteriole (increasing blood flow into the glomerulus) while constricting the efferent arteriole (maintaining filtration pressure). This selective vascular effect increases the pressure gradient across the glomerular capillaries, promoting filtration without increasing overall renal blood flow proportionally. Silver (2006) noted that ANP's renal effects include increasing GFR, inhibiting sodium reabsorption, and suppressing renin release, all of which reduce cardiac preload.[2]
Protecting Against Diabetic Kidney Disease
Inoue et al. (2025) provided direct evidence that natriuretic peptide/GC-A signaling protects against diabetic kidney disease. In mice with streptozotocin-induced diabetes, genetic deletion of GC-A signaling accelerated kidney damage. The combination of impaired natriuretic peptide signaling and high-protein diet worsened diabetic kidney disease, with increased albuminuria and glomerular damage. Finerenone (a mineralocorticoid receptor antagonist) rescued the phenotype, suggesting that the protective mechanism involves opposition to aldosterone-mediated kidney injury.[4]
Kidney Disease and Natriuretic Peptide Clearance
Yang et al. (2020) reviewed an important complication: the kidneys clear natriuretic peptides from the circulation. In patients with end-stage kidney disease, BNP and NT-proBNP levels are elevated not only from cardiac dysfunction but also from reduced renal clearance. This makes interpreting natriuretic peptide levels in kidney disease patients challenging. However, Yang et al. found that even in end-stage kidney disease, higher natriuretic peptide levels still predict worse cardiovascular outcomes, suggesting the peptides retain their pathophysiological significance regardless of impaired clearance.[11]
Beyond Heart and Kidneys: Metabolic Effects
Natriuretic peptides also regulate metabolism. Moro (2016) reviewed evidence that a defective natriuretic peptide system is linked to obesity and predicts the risk of type 2 diabetes. Obese individuals have lower circulating ANP and BNP levels than lean individuals, a paradox given that obesity increases cardiac workload. This "natriuretic peptide deficiency" in obesity appears to be caused by increased expression of the clearance receptor NPRC in adipose tissue, which removes natriuretic peptides from circulation before they can exert their effects.[5]
The metabolic effects of natriuretic peptides include:
- Lipolysis: ANP and BNP activate hormone-sensitive lipase in adipocytes through cGMP/PKG, promoting fat breakdown
- Browning of white fat: natriuretic peptides promote thermogenic gene expression in white adipose tissue
- Insulin sensitivity: cGMP signaling in skeletal muscle improves glucose uptake
This metabolic dimension means that the protective effects of natriuretic peptides extend beyond hemodynamics. The heart, kidneys, vasculature, and adipose tissue form an integrated system where natriuretic peptide signaling coordinates responses across multiple organs. For context on other peptide systems that regulate metabolism, see FGF21: the metabolic hormone from your liver.
Natriuretic Peptide Resistance in Heart Failure
A central paradox of heart failure is that natriuretic peptide levels are markedly elevated, yet the expected protective effects (vasodilation, natriuresis, anti-remodeling) are insufficient. This phenomenon, termed "natriuretic peptide resistance," has multiple proposed mechanisms.
Kuwahara (2021) and Volpe et al. (2019) identified several contributing factors: downregulation of GC-A receptors in target tissues, increased activity of neprilysin (the enzyme that degrades natriuretic peptides), elevated NPRC clearance receptor expression, and competitive inhibition by the sustained RAAS activation in heart failure.[3][12]
This understanding of natriuretic peptide resistance led directly to a major therapeutic breakthrough: sacubitril/valsartan (Entresto). Sacubitril inhibits neprilysin, preventing degradation of endogenous ANP and BNP, while valsartan blocks the angiotensin II receptor. The PARADIGM-HF trial showed this combination reduced cardiovascular death and heart failure hospitalization by 20% compared to enalapril alone. Panneflek et al. (2025) described this as validation of the principle that augmenting natriuretic peptide signaling provides cardiovascular protection beyond standard RAAS blockade.[6]
Emerging Therapeutic Approaches
Designer Natriuretic Peptides
Kodal et al. (2025) designed a once-weekly C-type natriuretic peptide analogue for heart failure with preserved ejection fraction (HFpEF). The analogue incorporated five strategic amino acid substitutions and a fatty acid protractor to improve stability and extend the half-life from minutes (native CNP) to a clinically practical weekly dosing schedule. Preclinical testing showed cardiovascular effects consistent with CNP's anti-fibrotic and vasodilatory properties.[13]
Snake Venom-Derived Peptides
Tourki et al. (2019) demonstrated that Lebetin 2, a BNP-like peptide from viper venom, provided both immediate and prolonged cardioprotection after ischemia-reperfusion injury. The venom-derived peptide offered a natural starting point for engineering modified natriuretic peptides with improved stability and tissue targeting.[10]
Limitations
Several gaps remain in understanding natriuretic peptide-mediated protection. Most mechanistic studies use animal models (primarily mice with genetic modifications of natriuretic peptide receptors), and direct translation to human cardiac and renal protection at the molecular level is incomplete. The relative contributions of ANP versus BNP to specific protective effects are difficult to disentangle because they share the GC-A receptor.
Natriuretic peptide levels vary widely between individuals and are affected by age, sex, body mass index, and renal function. The "natriuretic peptide deficiency" hypothesis in obesity, while supported by observational data, has not been proven causally in human interventional studies.
The emerging designer peptide approaches (CNP analogues, venom-derived peptides) are in early preclinical or phase I stages. Whether they will demonstrate the efficacy suggested by the mechanistic rationale remains to be determined in large clinical trials.
The Bottom Line
ANP, BNP, and CNP protect the heart and kidneys through cGMP-PKG signaling, which drives vasodilation, natriuresis, anti-hypertrophy, and anti-fibrosis effects. Natriuretic peptides directly oppose the RAAS at every level. In heart failure, natriuretic peptide resistance develops despite elevated levels, leading to the therapeutic strategy of augmenting natriuretic peptide signaling with neprilysin inhibitors (sacubitril/valsartan). The system also regulates metabolism, with natriuretic peptide deficiency linked to obesity and diabetes risk. Designer CNP analogues and venom-derived natriuretic peptides represent emerging therapeutic approaches.